🔗 Share this article

While America proceeds with sweeping adjustments to its immunization recommendations, an unexpected name appears unexpectedly: Dr. Tracy Beth Høeg, a Danish American physician and epidemiologist who first made her name by expressing skepticism about COVID-19 vaccines in the pandemic and has focused upon potential fatalities following COVID-19 vaccination in her brief time at the Food and Drug Administration.

Proposed Shifts to Childhood Vaccine Program

Public health authorities were set to reveal radical changes to the childhood vaccine schedule recently, aligning the US with the Danish immunization schedule, sources say – a significant shift that would place the US out of alignment with many the world with little proof for public health gain. The planned update has been postponed until the new year.

Instead of the director of the vaccine center, Høeg is listed to present at the event. She was just designated temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to lead the office this calendar year.

A New Direction at the Agency

Høeg's temporary position could signify a tighter collaboration between the pharmaceutical and biologics divisions as Høeg and Prasad consolidate power at the FDA – and it suggests a increased emphasis upon reevaluating long-standing immunizations at the FDA.

The new acting director has repeatedly called for discontinuing specific pediatric immunization guidelines in the US in order to be more in line with the Danish model, a society with nationalized medicine and a population approximately the population of the state of Wisconsin.

So far statements, she has kept her attention on vaccination policy – typically the responsibility of Prasad, chief of the FDA’s CBER – as opposed to drug regulation.

Questions Over Qualifications

The appointee has no obvious track record in drug development, approval processes or leadership, which has been standard for former directors of the biologics center. She has served at the FDA as a top consultant to the agency head and CBER since spring.

“It seems she lacks to have any of the qualifications” for overseeing the CDER, said Dr. Jonathan Howard. “She lacks experience running a scientific study. She is not versed in managing a major agency. She has no expertise in pharmaceutical oversight.”

Previous directors of CBER would “grasp regulatory frameworks and the research of medication creation”, commented Janet Woodcock. “Objectively, she doesn’t have the kind of background that former directors who led CBER have had.”

CDER has an enormous portfolio at the FDA, Woodcock emphasized.

“The public just zeroes in on the new drug program, but the generic drug division approves a multitude of generic drugs. There is also a biosimilars program, over-the-counter program and more, and each of these have to be looked after,” Woodcock noted. “The thing you neglect, that’s the thing that I always told people is going to bite you.”

Additionally, a major management element to the position, which manages more than 5,000 personnel. “It is a enormous administrative position, if you perform it correctly,” the former official added.

Agency Reaction and Contentious Policies

Regarding inquiries about Dr. Høeg's fitness for the role and whether this selection indicates increased cooperation among FDA leaders on immunizations, a spokesperson said that the “questions are based on inaccurate premises”.

“Her resume is consistent with the responsibilities of her position,” the official said, noting the period Dr. Høeg spent guiding the FDA commissioner on “drug safety and regulatory science, including computerized risk analysis and immunization monitoring”.

As the temporary head, Høeg takes over the commissioner’s controversial expedited review system, a contentious expedited medication authorization process that allegedly concerned her preceding directors. “By what process are these medications being picked for this voucher program? Who is making the calls?” Howard questioned. “There’s a lot of confidentiality occurring at the agency right now.”

Overall, he said, “the FDA appears to be shifting towards less stringent oversight of all drugs, with the exception of immunizations.”

Documented Past Work on Vaccines

Concerning immunizations, Høeg has a more established, if concerning, past, critics observe. She released a study using non-validated crowd-sourced reports to assess the incidence of heart inflammation after Covid immunization. She counseled the Florida top health official Joseph Ladapo, who allegedly have changed statistics to suggest Covid vaccines are pose a greater threat than they are.

Among her “wish list” for the new federal leadership encompassed altering rules for recently developed shots and halting “non-essential” vaccines, she remarked following the vote on a podcast. At the agency, Dr. Høeg has reportedly floated the idea of preventing teenage boys from getting COVID-19 vaccines.

“She’s an all-around true believer who starts off with her conclusions and tailors the evidence to accommodate the data in a extremely deceptive, fraudulent manner,” Howard said.

Consolidating Power and a “Revenge Tour”

Dr. Høeg joined other dissenters, {like|